Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2018

Open Access 01-12-2018 | Original investigation

Interaction between endothelial nitric oxide synthase rs1799983, cholesteryl ester-transfer protein rs708272 and angiopoietin-like protein 8 rs2278426 gene variants highly elevates the risk of type 2 diabetes mellitus and cardiovascular disease

Author: Dalia El-Lebedy

Published in: Cardiovascular Diabetology | Issue 1/2018

Login to get access

Abstract

Background

The aim of the present study was to examine the association of angiopoietin-like proteins-8 (ANGPTL8) rs2278426, cholesteryl ester-transfer protein (CETP) rs708272 and endothelial nitric oxide synthase (NOS3) rs1799983 variants with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), and to investigate the effect of the potential interaction between these variants on disease risk.

Methods

Our study included 272 subjects classified into 68 patients with T2DM, 68 patients with T2DM complicated with CVD and 136 control subjects. ANGPTL8 c194C>T, CETP Taq1B and NOS3 G894T polymorphisms were genotyped using TaqMan® SNP Genotyping Assay.

Results

The presence of NOS3, ANGPTL8, and homozygous CETP B1 variants were associated with increased risk of T2DM by 3.07-, 2.33- and 1.75-fold, respectively. NOS3 variant was associated with 3.08-fold increased risk of CVD (95% CI 1.70–5.60), while ANGPTL8 C allele was associated with 2.8-fold increased risk of CVD in T2DM patients (95% CI 1.13–6.97). Concomitant presence of both, CETP B1 and NOS3 T allele, associated with increased risk of T2DM, CVD and CVD in T2DM by 8.36-, 6.33- and 7.87-fold, respectively, while concomitant presence of ANGPTL8 variant with either CETP B1 or NOS3 T allele was not associated with increased risk of T2DM or CVD. However, concomitant presence of the three variants together elevated the risk of T2DM by 13.22-fold (p = 0.004), CVD risk by 8.86-fold (p = 0.03) and highly elevated the risk of CVD in T2DM patients by 13.8-fold (p = 0.008).

Conclusions

Concomitant presence of CETP B1, NOS3 T and ANGPTL8 T alleles augments the risk of CVD and T2DM. Further studies to clarify the mechanism of gene–gene interaction in the pathogenesis of CVD and T2DM are needed.
Literature
1.
Chaudhary R, Likidlilid A, Thavatchai Peerapatdit T, Damras Tresukosol D, Srisuma S, Ratanamaneechat S, Sriratanasathavorn C. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 2012;11:36–47.CrossRefPubMedPubMedCentral
2.
El-Lebedy D, Kafoury M, Abd-El Haleem D, Ibrahim A, Awadallah E, Ashmawy I. Paraoxonase-1 gene Q192R and L55 M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus. J Diabetes Metab Disord. 2014;13:125–31.CrossRef
3.
El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular Disease. Cardiovasc Diabetol. 2016;15:12–22.CrossRefPubMedPubMedCentral
4.
El-Lebedy D, Rasheed E, Kafoury M, Abd-El Haleem D, Awadallah E, Ashmawy I. Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus. J Diabetes Complications. 2016;30(4):580–5.CrossRefPubMed
5.
Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432–46.CrossRefPubMed
6.
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.CrossRefPubMed
7.
Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012;303:E334–51.CrossRefPubMedPubMedCentral
8.
Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuela DM, Murphy AJ, Cohen JC, Hobbs HH. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109:19751–6.CrossRefPubMed
9.
Kugelberg E. Diabetes: betatrophin inducing beta-cell expansion to treat diabetes mellitus? Nat Rev Endocrinol. 2013;9:379.CrossRefPubMed
10.
Lickert H. Betatrophin fuels beta cell proliferation: first step toward regenerative therapy? Cell Metab. 2013;18(1):5–6.CrossRefPubMed
11.
Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2012;424:786–92.CrossRefPubMed
12.
13.
Fu Z, Abou-Samra AB, Zhang R. A Lipasin/ANGPTL8 monoclonal antibody lowers mouse serum triglycerides involving increased postprandial activity of the cardiac lipoprotein lipase. Sci Rep. 2015;5:18502.CrossRefPubMedPubMedCentral
14.
Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment individual patient meta-analysis of 13677 subjects. Circulation. 2005;111:278–87.CrossRefPubMed
15.
De Grooth GJ, Klerkx AHEM, Stroes ESG, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res. 2004;45:1967–74.CrossRefPubMed
16.
Padmaja N, Kumar RM, Balachander J, Adithan C. Cholesteryl ester transfer protein TaqIB, − 629C/A and I405 V polymorphisms and risk of coronary heart disease in an Indian population. Clin Chim Acta. 2009;402:139–45.CrossRefPubMed
17.
Kashani Farid MA, Azizi F, Hedayati M, Daneshpour MS, Shamshiri AR, Siassi F. Association between CETP Taq1B and LIPC − 514C/T polymorphisms with the serum lipid levels in a group of Tehran’s population: a cross sectional study. Lipids Health Dis. 2010;9:96.CrossRefPubMedPubMedCentral
18.
Dixit M, Bhattacharya S, Mittal B. Association of CETP TaqI and APOE polymorphisms with type II diabetes mellitus in North Indians: a case control study. BMC Endocr Disord. 2005;5:7.CrossRefPubMedPubMedCentral
19.
Chaaba R, Hammami S, Attia N, Smaoui M, Masmoudi AS, Mahjoub S, Ben Hamda K, Hammami M. Association of plasma cholesteryl ester transfer protein activity and polymorphism with coronary artery disease extent in Tunisian type II diabetic patients. Clin Biochem. 2005;38:373–8.CrossRefPubMed
20.
Hsieh MC, Tien KJ, Chang SJ, Lo CS, Hsin SC, Hsiao JY, Hsu SC, Liang HT, Chen HC, Shin SJ, Lin SR. Cholesteryl ester transfer protein B1B1 genotype as a predictor of coronary artery disease in Taiwanese with type 2 diabetes mellitus. Metabolism. 2007;56:745–50.CrossRefPubMed
21.
Relvas WG, Izar MC, Helfenstein T, Fonseca MI, Colovati M, Oliveira A, Ihara SS, Han SW, Las Casas AA Jr, Fonseca FA. Relationship between gene polymorphisms and prevalence of myocardial infarction among diabetic and non-diabetic subjects. Atherosclerosis. 2005;178:101–5.CrossRefPubMed
22.
Kawasaki I, Tahara H, Emoto M, Shoji T, Nishizawa Y. Relationship between TaqIB cholesteryl ester transfer protein gene polymorphism and macrovascular complications in Japanese patients with type 2 diabetes. Diabetes. 2002;51:871–4.CrossRefPubMed
23.
Dellamea BS, Pinto LC, Leitão CB, Santos KG, Canani LH. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. BMC Med Genet. 2014;15:9.CrossRefPubMedPubMedCentral
24.
Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens. 2002;20(10):2023–7.CrossRefPubMed
25.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl. 1):S81–90.CrossRef
26.
Azad N, Agrawal L, Emanuele NV, Klein R, Bahn GD, Reaven P. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2014;57(6):1124–31.CrossRefPubMed
27.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefPubMed
28.
Gerstein HC, Miller ME, Byington R, Goff DC, Bigger JT, Buse JB. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMed
29.
Felehgari V, Rahimi Z, Mozafari H, Vaisi-Raygani A. ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria. Mol Cell Biochem. 2011;346:23–30.CrossRefPubMed
30.
Liu SM, Zhou X, Zheng F, Li X, Liu F, Zhang HM, Xie Y. Novel mutations found in mitochondrial diabetes in Chinese Han population. Diabetes Res Clin Pract. 2007;76:425–35.CrossRefPubMed
31.
Bellini MH, Figueira MN, Piccoli MF, Marumo JT, Cendoroglo MS, Neto MC, Dalboni MA, Batista MC, Goes MA, Schor N. Association of endothelial nitric oxide synthase gene intron 4 polymorphism with end-stage renal disease. Nephrology. 2007;12:289–93.CrossRefPubMed
32.
Möllsten A, Lajer M, Jorsal A, Tarnow L. The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Mol Genet Metab. 2009;97:80–4.CrossRefPubMed
33.
Omar SA, Webb AJ, Lundberg JO, Weitzberg E. Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases. J Intern Med. 2016;279(4):315–36.CrossRefPubMed
34.
Ren X, Ren L, Wei Q, Shao H, Chen L, Liu N. Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol. 2017;16:52.CrossRefPubMedPubMedCentral
35.
Zeng Z, Li L, Zhang Z, Li Y, Wei Z, Huang K, He L, Shi Y. A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy. Hum Genet. 2010;127(4):373–81.CrossRefPubMed
36.
Zintzaras E, Papathanasiou A, Stefanidis I. Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a huge review and meta-analysis. Genet Med. 2009;11(10):695–706.CrossRefPubMed
37.
Chand S, Chue CD, Edwards NC, Hodson J, Simmonds MJ, Hamilton A, Gough SC, Harper L, Steeds RP, Townend JN, Ferro CJ, Borrows R. Endothelial nitric oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney disease. PLoS ONE. 2015;10(1):e0116160.CrossRefPubMedPubMedCentral
38.
Kerkeni M, Addad F, Chauffert M, Myara A, Ben Farhat M, Miled A, Maaroufi K, Trivin F. Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. Clin Chem. 2006;52:53–8.CrossRefPubMed
39.
Motawi T, Shaker O, Taha M, Sedrak H, Nabil M. Endothelial nitric oxide synthase and angiotensinogen gene polymorphism in coronary artery diseases in Egypt. Angiology. 2011;62:191–7.CrossRefPubMed
40.
Liyou N, Simons L, Friedlander Y, Simons J, McCallum J, O’Shaughnessy K, Davis D, Johnson A. Coronary artery disease is not associated with the E298D variant of the constitutive, endothelial nitric oxide synthase gene. Clin Genet. 1998;54:528–9.CrossRefPubMed
41.
Andrikopoulos GK, Grammatopoulos DK, Tzeis SE, Zervou SI, Richter DJ, Zairis MN, Gialafos EJ, Sakellariou DC, Foussas SG, Manolis AS, Stefanadis CI, Toutouzas PK, Hillhouse EW. GEMIG study investigators. Association of the 894G>Tpolymorphism in the endothelial nitric oxide synthase gene with risk of acute myocardial infarction. BMC Med Genet. 2008;9:43.CrossRefPubMedPubMedCentral
42.
Ragia G, Nikkolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Ougioukas G, Manolopoulos VG. Endothelial nitric oxide synthase gene polymorphisms − 786 T>C and 894 G>T in coronary artery bypass graft surgery patients. Hum Genomics. 2010;4:375–83.CrossRefPubMedPubMedCentral
43.
Matsha TE, Pheiffer C, Mutize T, Erasmus RT, Kengne AP. Glucose tolerance, MTHFR C677T and NOS3 G894T polymorphisms and global DNA methylation in Mixed Ancestry African Individuals. J Diabetes Res. 2016;2016:8738072.CrossRefPubMedPubMedCentral
44.
Wiltshire EJ, Peña AS, MacKenzie K, Bose-Sundernathan T, Gent R, Couper JJ. A NOS3 polymorphism determines endothelial response to folate in children with type 1 diabetes or obesity. J Pediatr. 2015;166(2):319–325. e1.CrossRefPubMed
45.
Nilsson E, Matte A, Perfilyev A, de Mello VD, Käkelä P, Pihlajamäki J, Ling C. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. J Clin Endocrinol Metab. 2015;100(11):E1491–501.CrossRefPubMedPubMedCentral
46.
Wang X, Guan Z, Chen Y, Dong Y, Niu Y, Wang J, Zhang T, Niu B. Genomic DNA hypomethylation is associated with neural tube defects induced by methotrexate inhibition of folate metabolism. PLoS ONE. 2015;10(3):e0121869.CrossRefPubMedPubMedCentral
47.
Yin Y, Ding X, Peng L, Hou Y, Ling Y, Gu M, Wang Y, Peng Y, Sun H. Increased serum ANGPTL8 concentrations in patients with prediabetes and type 2 diabetes. J Diabetes Res. 2017;2017:8293207.CrossRefPubMedPubMedCentral
48.
Hanson RL, Leti F, Tsinajinnie D, Kobes S, Puppala S, Curran JE, Almasy L, Lehman DM, Blangero J, Duggirala R, DiStefano JK. The Arg59Trp variant in ANGPTL8 (betatrophin) is associated with total and HDL-cholesterol in American Indians and Mexican Americans and differentially affects cleavage of ANGPTL3. Mol Genet Metab. 2016;118(2):128–37.CrossRefPubMedPubMedCentral
49.
Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Kavalakatt S, Khadir A, Behbehani K, Alarouj M, Bennakhi A, Elkum N. Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome. Cardiovasc Diabetol. 2016;15:25.CrossRefPubMedPubMedCentral
50.
Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Hu FB, Behbehani K, Elkum N. Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep. 2015;5:10949.CrossRefPubMedPubMedCentral
51.
Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol. 2014;2014:323407.CrossRefPubMedPubMedCentral
52.
Hu H, Sun W, Yu S, Hong X, Qian W, Tang B, Wang D, Yang L, Wang J, Mao C, Zhou L, Yuan G. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014;37(10):2718–22.CrossRefPubMed
53.
Abu-Farha M, Abubaker J, Noronha F, Al-Khairi I, Cherian P, Alarouj M, Bennakhi A, Elkum N. Lack of associations between betatrophin/ANGPTL8 level and C-peptide in type 2 diabetic subjects. Cardiovasc Diabetol. 2015;14:112.CrossRefPubMedPubMedCentral
54.
Gokulakrishnan K, Manokaran K, Pandey GK, Amutha A, Ranjani H, Anjana RM, Mohan V. Relationship of betatrophin with youth onset type 2 diabetes among Asian Indians. Diabetes Res Clin Pract. 2015;109(1):71–6.CrossRefPubMed
55.
Gómez-Ambrosi J, Pascual E, Catalán V, Rodríguez A, Ramírez B, Silva C, Gil MJ, Salvador J, Frühbeck G. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab. 2014;99(10):E2004–9.CrossRefPubMed
56.
Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH, Dallas Heart Study Investigators. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004;93(12):1473–80.CrossRefPubMed
57.
Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707–13.CrossRefPubMedPubMedCentral
58.
Abu-Farha M, Melhem M, Abubaker J, Behbehani K, Alsmadi O, Elkum N. ANGPTL8/Betatrophin R59W variant is associated with higher glucose level in non-diabetic Arabs living in Kuwaits. Lipids Health Dis. 2016;15:26.CrossRefPubMedPubMedCentral
59.
Goring ME, Leibovitch M, Gea-Mallorqui E, Karls S, Richard F, Hanic-Joyce PJ, Joyce PB. The ability of an arginine to tryptophan substitution in Saccharomyces cerevisiae tRNA nucleotidyltransferase to alleviate a temperature-sensitive phenotype suggests a role for motif C in active site organization. Biochim Biophys Acta. 2013;1834:2097–106.CrossRefPubMed
60.
Rani DS, Dhandapany PS, Nallari P, Narasimhan C, Thangaraj K. A novel arginine to tryptophan (R144W) mutation in troponin T (cTnT) gene in an Indian multigenerational family with dilated cardiomyopathy (FDCM). PLoS ONE. 2014;9:e101451.CrossRefPubMedPubMedCentral
61.
Heilbronn LK, Noakes M, Clifton PM. Association between HDL-cholesterol and the Taq1B polymorphism in the cholesterol ester transfer protein gene in obese women. Atherosclerosis. 2002;162:419–24.CrossRefPubMed
62.
Cahua-Pablo JÁ, Cruz M, Méndez-Palacios A, Antúnez-Ortiz DL, Vences-Velázquez A, del Carmen Alarcón-Romero L, Parra EJ, Tello-Flores VA, Leyva-Vázquez MA, Valladares-Salgado A, Pérez-Macedonio CP, Flores-Alfaro E. Polymorphisms in the LPL and CETP genes and haplotype in the ESR1gene are associated with metabolic syndrome in women from Southwestern Mexico. Int J Mol Sci. 2015;16(9):21539–54.CrossRefPubMedPubMedCentral
63.
López-Ríos L, Nóvoa FJ, Chirino R, Varillas F, Boronat-Cortés M, Wägner AM. Interaction between cholesteryl ester transfer protein and hepatic lipase encoding genes and the risk of type 2 diabetes: results from the Telde study. PLoS ONE. 2011;6(11):e27208.CrossRefPubMedPubMedCentral
64.
Rahimi Z, Nourozi-Rad R, Vaisi-Raygani A, Saidi MR, Rahimi Z, Ahmadi R, Yarani R, Hamzehee K, Parsian A. Association between cholesteryl ester transfer protein TaqIB variants and risk of coronary artery disease and diabetes mellitus in the population of Western Iran. Genet Test Mol Biomarkers. 2012;15:813–9.CrossRef
65.
Girona J, Ibarretxe D, Plana N, Guaita-Esteruelas S, Amigo N, Heras M, Masana L. Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Cardiovasc Diabetol. 2016;15(1):107.CrossRefPubMedPubMedCentral
Metadata
Title
Interaction between endothelial nitric oxide synthase rs1799983, cholesteryl ester-transfer protein rs708272 and angiopoietin-like protein 8 rs2278426 gene variants highly elevates the risk of type 2 diabetes mellitus and cardiovascular disease
Author
Dalia El-Lebedy
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2018
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-018-0742-8

Other articles of this Issue 1/2018

Cardiovascular Diabetology 1/2018 Go to the issue

Original investigation

Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study

Original investigation

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Original investigation

Association between triglyceride glucose index and arterial stiffness in Korean adults

Original investigation

Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology

Original investigation

Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: a matched case–control analysis

Review

Reduced coronary collateralization in type 2 diabetic patients with chronic total occlusion
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits